ConductScience.org, home
PDE4B: phosphodiesterase 4B
API referenceFor AI assistants

Gene · 5142

Papers1,785

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 1,785

Download this page as JSON
TitleJournalYearPMIDFound bySource
Nerandomilast is Associated With Altered Alveolar Epithelial Cell State Dynamics While Attenuating Fibrotic Remodeling in Pulmonary Fibrosis.Genes Cells202642827411PubTator, text miningPubMed
Endoplasmic reticulum stress and maladaptive repair in fibrotic interstitial lung diseases: A human-evidence-based narrative review.Ther Adv Respir Dis202642813994PubTator, text miningPubMed
The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis.Expert Rev Clin Pharmacol202642768757PubTator, text miningPubMed
MiR-23b-3p exerts a protective effect in hypertensive nephropathy by inhibiting fibrosis and inflammation.Am J Hypertens202642726087PubTator, text miningPubMed
Reconfiguring the macrophage-centric intercellular network in pulmonary fibrosis: Emerging perspectives and therapeutic opportunities.Pharmacol Res202642705427PubTator, text miningPubMed
ALDH2 regulates oxaliplatin sensitivity via PDE4B in p53-mutant colorectal cancer.Int J Med Sci202642694559PubTator, text miningPubMed
Pharmacokinetics and Safety of Nerandomilast in Healthy Volunteers.Eur J Drug Metab Pharmacokinet202642563128PubTator, text miningPubMed
Elucidating the molecular mechanisms of paeoniflorin intervention in oral lichen planus: a computational biology and bioinformatics-based research strategy.Front Bioinform202642539528PubTator, text miningPubMed
Precision Modulation of the PDE4 Pathway: The Emerging Role of Nerandomilast in Pulmonary Fibrosis.J Pharm Technol202642490950PubTator, text miningPubMed
Selective phosphodiesterase 4B inhibition in fibrotic lung disease: a scoping review of vascular-immune mechanisms and extrapulmonary implications.Eur Respir Rev202642486502PubTator, text miningPubMed
Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development.
Epilepsia202642470358PubTator, text miningPubMed
Shared genetic architecture and neurobiological pathways of problematic alcohol use and anxiety disorders.Neuropsychopharmacology202642443535PubTator, text miningPubMed
[Comparative analysis of drug therapy for fibrotic interstitial lung diseases based on results of phase 3 trials].Pneumologie202642409049PubTator, text miningPubMed
The selective degradation of PDE4B shortform, using a PROTAC, leads to inhibition of several hallmarks of cancer in HCT116 cells.Br J Pharmacol202642380049PubTator, text miningPubMed
[Research advancements in phosphodiesterase 4 inhibition for the treatment of pulmonary fibrosis and associated mechanisms].Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi202642373531PubTator, text miningPubMed
A Scoping Review of Emerging Treatments in the Pipeline for Idiopathic Pulmonary Fibrosis: Future Perspectives.Biomedicines202642351721PubTator, text miningPubMed
Progressive pulmonary fibrosis: a state-of-the-art review.Eur Respir J202642276742PubTator, text miningPubMed
Genome-Wide Association Study Identifies Human Genetic Variants Associated with Systemic Chronic Inflammation.OMICS202642275006PubTator, text miningPubMed
Therapeutic Effects of Phosphodiesterase Inhibitors on Hypertensive Disorders in Pregnancy and Fetal Growth Restriction: A Drug Targeted Mendelian Randomization Study.Curr Med Chem202642227534PubTator, text miningPubMed
Natural PDE4 inhibitors from plants: A comprehensive review of discovery, structure-activity relationships, and clinical translation potential.Eur J Med Chem202642166818PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/5142/papers

API referenceFor AI assistants